PHAT
Phathom·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PHAT
Phathom Pharmaceuticals, Inc.
A biopharmaceutical company focused on developing novel treatments for gastrointestinal diseases and disorders
100 Campus Drive
, Suite 102
, Florham Park
, New Jersey 07932
--
Phathom Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on January 9, 2018. The Company is a biopharmaceutical company focused on the development and commercialization of new therapies for the treatment of gastrointestinal diseases or GI diseases.
Earnings Call
Q1/2025
Estimate EPS-1.07
Actual EPS-1.07
Estimate Revenue29.02M
Actual Revenue28.52M
Contradictions Unveiled: Analyzing the Impact of Citizen Petition Timelines and DTC Campaign Effectiveness in 2025 Q1
May 06,2025 10:34
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.89
Actual EPS-0.79
Estimate Revenue35.58M
Actual Revenue39.50M
Phathom Pharmaceuticals Q2 2025: Unpacking Contradictions in Growth Strategies and Market Focus
Aug 07,2025 05:35
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PHAT has released its 2025 Q3 earnings. EPS was reported at -0.15, versus the expected -0.41, beating expectations. The chart below visualizes how PHAT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PHAT has released its 2025 Q3 earnings report, with revenue of 49.50M, reflecting a YoY change of 202.74%, and net profit of -29.97M, showing a YoY change of 64.98%. The Sankey diagram below clearly presents PHAT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
